Tofersen Patent Expiration
Tofersen is Used for treating amyotrophic lateral sclerosis (ALS) in adult patients with a mutation in the SOD1 gene. It was first introduced by Biogen Ma Inc
Tofersen Patents
Given below is the list of patents protecting Tofersen, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Qalsody | US10385341 | Compositions for modulating SOD-1 expression | Apr 01, 2035 | Biogen Ma |
| Qalsody | US10669546 | Compositions for modulating SOD-1 expression | Apr 01, 2035 | Biogen Ma |
| Qalsody | US10968453 | Compositions for modulating SOD-1 expression | Apr 01, 2035 | Biogen Ma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Tofersen's patents.
Latest Legal Activities on Tofersen's Patents
Given below is the list recent legal activities going on the following patents of Tofersen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10385341 |
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10968453 |
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10669546 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US10669546 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US10385341 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US10968453 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 01 Feb, 2024 | US10669546 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 01 Feb, 2024 | US10968453 |
| Email Notification Critical
| 01 Feb, 2024 | US10669546 |
| Email Notification Critical
| 01 Feb, 2024 | US10968453 |
Tofersen's Family Patents
